{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:26:55Z","timestamp":1787236015388,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer of unknown primary (CUP) is usually treated with nonselective and empirical chemotherapy; however, its prognosis is generally poor, with a median survival of less than a year. Thus, clinicians eagerly await the development of more effective treatment strategies. In recent years, advances in next-generation sequencing (NGS) have made it possible to analyze comprehensively the genome of individual cancers. NGS has identified many genomic alterations, some of which are potential molecular targets of specific agents. We report a case of CUP that was successfully treated with targeted therapy directed by the genomic data obtained from an NGS-based multiplex assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 52-year-old Asian woman with right hip joint pain underwent fluorodeoxyglucose-positron emission tomography\/computed tomography, which showed multiple metastatic tumors in her right hip joint, thyroid gland, lung, and vertebrae. Brain magnetic resonance imaging showed multiple cerebral metastases. Additional tests, including pathology examination and conventional epidermal growth factor receptor (\n                      <jats:italic>EGFR<\/jats:italic>\n                      ) gene mutation analysis (single-strand conformation polymorphism assay), could not identify the primary origin of the tumors, so the patient was diagnosed with CUP. After empirical chemotherapy for CUP, an NGS-based multiplex assay performed using a resected specimen of thyroid tumor detected the\n                      <jats:italic>EGFR<\/jats:italic>\n                      mutation c.2573\u2009T\u2009&gt;\u2009G p.Leu858Arg (L858R). Her treatment was changed to erlotinib, an\n                      <jats:italic>EGFR<\/jats:italic>\n                      tyrosine-kinase inhibiter, which dramatically shrank the tumors and decreased her serum carcinoembryonic antigen level. She achieved long-term disease control and survived for 2\u2009years and 9\u2009months from the first diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case might support the strategy that NGS-based multiplex assays could identify actionable molecular targets for individual patients with CUP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07640-4","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T01:03:05Z","timestamp":1606870985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cancer of unknown primary with EGFR mutation successfully treated with targeted therapy directed by clinical next-generation sequencing: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Yosuke","family":"Mitani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayuki","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigemi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"issue":"9824","key":"7640_CR1","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","volume":"379","author":"N Pavlidis","year":"2012","unstructured":"Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012;379(9824):1428\u201335.","journal-title":"Lancet."},{"issue":"8","key":"7640_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJMra1303917","volume":"371","author":"GR Varadhachary","year":"2014","unstructured":"Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med. 2014;371(8):757\u201365.","journal-title":"N Engl J Med"},{"issue":"18","key":"7640_CR3","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1158\/1078-0432.CCR-14-0603","volume":"20","author":"AM Tsimberidou","year":"2014","unstructured":"Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. 2014;20(18):4827\u201336.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"7640_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/jjco\/hyw018","volume":"46","author":"T Kou","year":"2016","unstructured":"Kou T, Kanai M, Matsumoto S, Okuno Y, Muto M. The possibility of clinical sequencing in the management of cancer. Jpn J Clin Oncol. 2016;46(5):399\u2013406.","journal-title":"Jpn J Clin Oncol"},{"issue":"13","key":"7640_CR5","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1158\/0008-5472.CAN-15-3043","volume":"76","author":"JJ Wheler","year":"2016","unstructured":"Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, et al. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res. 2016;76(13):3690\u2013701.","journal-title":"Cancer Res"},{"issue":"5","key":"7640_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/jnci\/dji055","volume":"97","author":"H Shigematsu","year":"2005","unstructured":"Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339\u201346.","journal-title":"J Natl Cancer Inst"},{"issue":"25","key":"7640_CR7","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380\u20138.","journal-title":"N Engl J Med"},{"issue":"7","key":"7640_CR8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-Pemetrexed in EGFR T790M-positive lung Cancer. N Engl J Med. 2017;376(7):629\u201340.","journal-title":"N Engl J Med"},{"issue":"7","key":"7640_CR9","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1093\/annonc\/mdr536","volume":"23","author":"K Hemminki","year":"2012","unstructured":"Hemminki K, Bevier M, Hemminki A, Sundquist J. Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol. 2012;23(7):1854\u201363.","journal-title":"Ann Oncol"},{"issue":"7","key":"7640_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ctrv.2013.03.001","volume":"39","author":"D Petrakis","year":"2013","unstructured":"Petrakis D, Pentheroudakis G, Voulgaris E, Pavlidis N. Prognostication in cancer of unknown primary (CUP): development of a prognostic algorithm in 311 cases and review of the literature. Cancer Treat Rev. 2013;39(7):701\u20138.","journal-title":"Cancer Treat Rev"},{"issue":"17","key":"7640_CR11","doi-asserted-by":"publisher","first-page":"4954","DOI":"10.1158\/1078-0432.CCR-07-1387","volume":"13","author":"W Pao","year":"2007","unstructured":"Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res. 2007;13(17):4954\u20135.","journal-title":"Clin Cancer Res"},{"key":"7640_CR12","volume-title":"SSED document","author":"U.S. Food and Drug Administration","year":"2017","unstructured":"U.S. Food and Drug Administration: SSED document (2017). https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf16\/P160045B.pdf. Accessed 22 Sep 2020."},{"key":"7640_CR13","volume-title":"SSED document","author":"U.S. Food and Drug Administration","year":"2017","unstructured":"U.S. Food and Drug Administration SSED document (2017): https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf17\/P170019B.pdf. Accessed 22 Sep 2020."},{"issue":"9","key":"7640_CR14","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1200\/JCO.2014.58.2007","volume":"33","author":"A Lopez-Chavez","year":"2015","unstructured":"Lopez-Chavez A, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R, et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol. 2015;33(9):1000\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"7640_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrc1836","volume":"6","author":"T Kondo","year":"2006","unstructured":"Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6(4):292\u2013306.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"7640_CR16","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052\u201366.","journal-title":"J Clin Invest"},{"issue":"2","key":"7640_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121\u20138.","journal-title":"Lancet Oncol"},{"issue":"17","key":"7640_CR18","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1200\/JCO.2000.18.17.3101","volume":"18","author":"E Briasoulis","year":"2000","unstructured":"Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic cooperative oncology group study. J Clin Oncol. 2000;18(17):3101\u20137.","journal-title":"J Clin Oncol"},{"issue":"18","key":"7640_CR19","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1200\/JCO.2003.12.104","volume":"21","author":"S Culine","year":"2003","unstructured":"Culine S, Lortholary A, Voigt JJ, Bugat R, Theodore C, Priou F, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French study group on carcinomas of unknown primary (GEFCAPI 01). J Clin Oncol. 2003;21(18):3479\u201382.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7640_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11060-016-2237-3","volume":"130","author":"DT Blumenthal","year":"2016","unstructured":"Blumenthal DT, Dvir A, Lossos A, Tzuk-Shina T, Lior T, Limon D, et al. Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients. J Neuro-Oncol. 2016;130(1):211\u20139.","journal-title":"J Neuro-Oncol"},{"issue":"1","key":"7640_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","volume":"1","author":"JS Ross","year":"2015","unstructured":"Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, et al. Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol. 2015;1(1):40\u20139.","journal-title":"JAMA Oncol"},{"issue":"12","key":"7640_CR22","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1093\/annonc\/mdx545","volume":"28","author":"AM Varghese","year":"2017","unstructured":"Varghese AM, Arora A, Capanu M, Camacho N, Won HH, Zehir A, et al. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. Ann Oncol. 2017;28(12):3015\u201321.","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07640-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07640-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07640-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T13:04:12Z","timestamp":1606914252000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07640-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7640"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07640-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"8 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study has been approved by Ethics Committee of Kyoto University Graduate School of Medicine (G692). Written informed consent to participate in this study was obtained from the patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication in the appropriate journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1177"}}